¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

2023 ³úÁ¹Áß Àç°³Åë ½ÉÆ÷Áö¾ö ¹× ´ëÇѳúÇ÷°ü³»Ä¡·áÀÇÇÐȸ Ãá°èº¸¼ö±³À° : 2023-02-25

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
2023 ³úÁ¹Áß Àç°³Åë ½ÉÆ÷Áö¾ö ¹× ´ëÇѳúÇ÷°ü³»Ä¡·áÀÇÇÐȸ Ãá°èº¸¼ö±³À° : 2023-02-25
±³À°ÀÏÀÚ : 2023-02-25
±³À°Àå¼Ò : Â÷¹ÙÀÌ¿À ÄÄÇ÷º½Ã ÁöÇÏ1Ãþ ±¹Á¦È¸ÀǽǠ 
±³À°ÁÖÁ¦ : 2023 ³úÁ¹Áß Àç°³Åë ½ÉÆ÷Áö¾ö ¹× ´ëÇѳúÇ÷°ü³»Ä¡·áÀÇÇÐȸ Ãá°èº¸¼ö±³À°
ÁÖÃÖ±â°ü : ´ëÇѳúÇ÷°ü³»Ä¡·áÀÇÇÐȸ
´ã´çÀÚ : Á¤È¿°æ
¿¬¶ôó : 02-2279-9560  
À̸ÞÀÏ : kones@konesonline.or.kr      
±³À°Á¾·ù : ½Å°æ¿Ü°ú      
Âü¼®¿¹»óÀοø : 100¸í
Èñ¸ÁÆòÁ¡ : 5Á¡  
Áö¿ª : °æ±âµµ
±³À°½Ã°£ : 5 ½Ã°£ 40ºÐ  
¼¼ºÎ¼ö°­·á : 100,000¿ø      
ºñ°í Á¤È¸¿ø(¿¬È¸ºñ³³ºÎ) 30,000¿ø / Á¤È¸¿ø(¿¬È¸ºñ¹Ì³³) 50,000¿ø / ÁØȸ¿ø 20,000¿ø / ºñȸ¿ø 100,000¿ø      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 02-25 Â÷¹ÙÀÌ¿À ÄÄÇ÷º½º ÁöÇÏ1Ãþ ±¹Á¦È¸ÀǽǠ10:00~10:30 Recent Debate in Large Vessel Occlusion Strokes - Support: Combined mechanical thrombectomy and IV Thrombolysis  ¹ÚÈñ±Ç(ÀÎÇϴ뺴¿ø ½Å°æ°ú) 
±³À°½Ã°£ 02-25 Â÷¹ÙÀÌ¿À ÄÄÇ÷º½º ÁöÇÏ1Ãþ ±¹Á¦È¸ÀǽǠ10:30~11:00 Recent Debate in Large Vessel Occlusion Strokes - Support: Primary mechanical thrombectomy  ÀÌÇö°ï(µ¿³²±Ç¿øÀڷº´¿ø ½Å°æ¿Ü°ú) 
±³À°½Ã°£ 02-25 Â÷¹ÙÀÌ¿À ÄÄÇ÷º½º ÁöÇÏ1Ãþ ±¹Á¦È¸ÀǽǠ11:00~11:20 Recent Debate in Large Vessel Occlusion Strokes - Endovascular Thrombectomy >24-hr From Stroke Symptom Onset  À̵¿ÈÆ(°¡Å縯´ë ¼ººó¼¾Æ®º´¿ø ½Å°æ¿Ü°ú) 
±³À°½Ã°£ 02-25 Â÷¹ÙÀÌ¿À ÄÄÇ÷º½º ÁöÇÏ1Ãþ ±¹Á¦È¸ÀǽǠ11:20~11:40 Endovascular Treatment of Acute Basilar Artery Occlusions - Review of the recently published trials  ¿ÀÀç»ó(¼øõÇâ´ë õ¾Èº´¿ø ½Å°æ¿Ü°ú) 
±³À°½Ã°£ 02-25 Â÷¹ÙÀÌ¿À ÄÄÇ÷º½º ÁöÇÏ1Ãþ ±¹Á¦È¸ÀǽǠ11:40~12:00 Endovascular Treatment of Acute Basilar Artery Occlusions - Stent retriever first  ÇÏ»ó¿ì(Á¶¼±´ëº´¿ø ½Å°æ¿Ü°ú) 
±³À°½Ã°£ 02-25 Â÷¹ÙÀÌ¿À ÄÄÇ÷º½º ÁöÇÏ1Ãþ ±¹Á¦È¸ÀǽǠ12:00~12:20 Endovascular Treatment of Acute Basilar Artery Occlusions - Contact aspiration first  ¼Õ¿ø¼ö(°æºÏ´ëº´¿ø ½Å°æ¿Ü°ú) 
Åä·Ð 02-25 Â÷¹ÙÀÌ¿À ÄÄÇ÷º½º ÁöÇÏ1Ãþ ±¹Á¦È¸ÀǽǠ12:20~12:30 Discussion – all attendees  () 
½Ä»ç 02-25 Â÷¹ÙÀÌ¿À ÄÄÇ÷º½º ÁöÇÏ1Ãþ ±¹Á¦È¸ÀǽǠ12:30~13:30 Lunch  () 
±³À°½Ã°£ 02-25 Â÷¹ÙÀÌ¿À ÄÄÇ÷º½º ÁöÇÏ1Ãþ ±¹Á¦È¸ÀǽǠ13:30~13:50 ±¹°¡ÀÇ·áÁ¤Ã¥ÀÇ ¹æÇâ - Á¦4Â÷ ÀÀ±ÞÀÇ·á±âº» °èȹ(2023-2027)  ÀåÇѼ®(Áß¾ÓÀÀ±ÞÀÇ·á¼¾ÅÍ ¼±ÀÓ¿¬±¸¿ø) 
±³À°½Ã°£ 02-25 Â÷¹ÙÀÌ¿À ÄÄÇ÷º½º ÁöÇÏ1Ãþ ±¹Á¦È¸ÀǽǠ13:50~14:10 ±¹°¡ÀÇ·áÁ¤Ã¥ÀÇ ¹æÇâ - ÇʼöÀÇ·á¿¡ °üÇÑ ½ÉÇ÷°ü°èÀÇ ½Ã°¢  À±Ã¢È¯(ºÐ´ç¼­¿ï´ëº´¿ø ¼øȯ±â³»°ú) 
±³À°½Ã°£ 02-25 Â÷¹ÙÀÌ¿À ÄÄÇ÷º½º ÁöÇÏ1Ãþ ±¹Á¦È¸ÀǽǠ14:10~14:30 ±¹°¡ÀÇ·áÁ¤Ã¥ÀÇ ¹æÇâ - ±Þ¼º±â³úÁ¹Áß ÀûÁ¤¼ºÆò°¡ °³¼±ÀÇ ¹æÇâ  ÃÖÁ¤³²(°Ç°­º¸Çè½É»çÆò°¡¿ø Æò°¡4ºÎ ºÎÀå) 
±³À°½Ã°£ 02-25 Â÷¹ÙÀÌ¿À ÄÄÇ÷º½º ÁöÇÏ1Ãþ ±¹Á¦È¸ÀǽǠ14:30~14:50 General Management of Acute Ischemic Stroke - Non-large vessel occlusions  ±èÈÆ(°¡Å縯´ë ºÎõ¼º¸ðº´¿ø ½Å°æ¿Ü°ú) 
±³À°½Ã°£ 02-25 Â÷¹ÙÀÌ¿À ÄÄÇ÷º½º ÁöÇÏ1Ãþ ±¹Á¦È¸ÀǽǠ14:50~15:10 General Management of Acute Ischemic Stroke - Critical care in severe AIS patients  À̼®À±(ÀÎÁ¦´ë ºÎ»ê¹éº´¿ø ½Å°æ°ú) 
È޽Ġ02-25 Â÷¹ÙÀÌ¿À ÄÄÇ÷º½º ÁöÇÏ1Ãþ ±¹Á¦È¸ÀǽǠ15:10~15:30 Coffee Break  () 
±³À°½Ã°£ 02-25 Â÷¹ÙÀÌ¿À ÄÄÇ÷º½º ÁöÇÏ1Ãþ ±¹Á¦È¸ÀǽǠ15:30~15:50 Role of IV Thrombolysis in the New Era of Endovascular Stroke Treatment - Alteplase is better?  ±èÇüÂù(ÀÎÁ¦´ë ÇØ¿î´ë¹éº´¿ø ½Å°æ°ú) 
±³À°½Ã°£ 02-25 Â÷¹ÙÀÌ¿À ÄÄÇ÷º½º ÁöÇÏ1Ãþ ±¹Á¦È¸ÀǽǠ15:50~16:10 Role of IV Thrombolysis in the New Era of Endovascular Stroke Treatment - Tenecteplase is better?  ¹Ý½ÂÇÊ(ºÐ´ç¼­¿ï´ëº´¿ø ½Å°æ¿Ü°ú) 
±³À°½Ã°£ 02-25 Â÷¹ÙÀÌ¿À ÄÄÇ÷º½º ÁöÇÏ1Ãþ ±¹Á¦È¸ÀǽǠ16:10~16:30 Primary stenting is feasible for ICAS-related Large Vessel Occlusions? - Interventional Neurologist¡¯s perspective: Rescue stenting  ±è¿ë¿ø(°æºÏ´ëº´¿ø ½Å°æ°ú) 
±³À°½Ã°£ 02-25 Â÷¹ÙÀÌ¿À ÄÄÇ÷º½º ÁöÇÏ1Ãþ ±¹Á¦È¸ÀǽǠ16:30~16:50 Primary stenting is feasible for ICAS-related Large Vessel Occlusions? - Endovascular Neurosurgeon¡¯s perspective: Primary stenting  Á¤¿µÁø(¿µ³²´ëº´¿ø ½Å°æ¿Ü°ú) 
Åä·Ð 02-25 Â÷¹ÙÀÌ¿À ÄÄÇ÷º½º ÁöÇÏ1Ãþ ±¹Á¦È¸ÀǽǠ16:50~17:00 Discussion – all attendees  () 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" 2023 ³úÁ¹Áß Àç°³Åë ½ÉÆ÷Áö¾ö ¹× ´ëÇѳúÇ÷°ü³»Ä¡·áÀÇÇÐȸ Ãá°èº¸¼ö±³À° : 2023-02-25""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û »ï¼º¼­¿ïº´¿ø 2023 Kore-Japan Joint Symposium on Gene therapy in Inborn Errors of Immunity : 2023-02-25
´ÙÀ½±Û ´ëÇÑ°æÃß¿¬±¸È¸ Á¦11ȸ Áõ·Ê Åä·Ðȸ : 2023-02-25
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20925 ÀüºÏ Á¦ 53Â÷ ´ëÇѳëÀκ´ÇÐȸ È£³²Áöȸ ÇмúÁý´äȸ : 2024-07-27 0 48 2024-05-28
20924 ¼­¿ï 2024 Á¦27ȸ ´ëÇѾȸ鼺ÇüÀç°ÇÇÐȸ Ãá°è Çмú´ëȸ : 2024-07-21 0 43 2024-05-28
20923 °æ±â 2024³â ÀÏ»ê¹éº´¿ø Á¤Çü¿Ü°ú ½ÉÆ÷Áö¾ö : 2024-07-21 0 39 2024-05-28
20922 ¼­¿ï 2024³â ü°èÀû ¹®Çå°íÂû(¸ÞŸºÐ¼®) ³í¹®Ãâ°£ ¿öÅ©¼¥ 2Â÷(2ÀÏÂ÷) : 2024-07-20 0 51 2024-05-28
20921 ¼­¿ï Á¦33Â÷ ´ç´¢º´ ¿¬±¸ ÇÏ°è¿öÅ©¼¥ : 2024-07-20 0 38 2024-05-28
20920 ¼­¿ï ´ëÇÑÁ¾¾ç³»°úÇÐȸ Recent updates in GU Cancers 2024 : 2024-07-19 0 73 2024-05-28
20919 ¼­¿ï 2024³â ü°èÀû ¹®Çå°íÂû(¸ÞŸºÐ¼®) ³í¹®Ãâ°£ ¿öÅ©¼¥ 2Â÷(1ÀÏÂ÷) : 2024-07-19 0 28 2024-05-28
20918 ¼­¿ï [¿Â¶óÀÎ] Áø´Ü¿ë ¹æ»ç¼± ¾ÈÀü°ü¸®Ã¥ÀÓÀÚ ¼±ÀÓ±³À° : 2024-07-14 0 40 2024-05-28
20917 °æºÏ 2024³â ´ëÇÑ°ñ´Ù°øÁõÇÐȸ ¿µ³² ¿¬¼ö°­Á : 2024-07-14 0 38 2024-05-28
20916 °æ±â ÀÎÁ¦´ëÇб³ ÀÏ»ê¹éº´¿ø ¼ÒÈ­±â³»°ú °³¿øÀÇ ¿¬¼ö°­Á : 2024-07-13 0 45 2024-05-28
20915 °æ±â 2024³â ÀÇÁ¤ºÎÀ»Áö´ëÇб³º´¿ø Á¦1ȸ ½Å°æ°ú °³¿øÀÇ ¿¬¼ö±³À° : 2024-07-13 0 43 2024-05-28
20914 ºÎ»ê Á¦6ȸ ºÎ»ê¼º¸ðº´¿ø ¼Ò¾Æû¼Ò³â°ú ½ÉÆ÷Áö¾ö : 2024-07-13 0 32 2024-05-28
20913 ¼­¿ï 2024 ´ëÇѽŰ泻ºÐºñ¿¬±¸È¸ ¿¬¼ö°­Á : 2024-07-13 0 36 2024-05-28
20912 ¼­¿ï ÀºÆò±¸ÀÇ»çȸ Á¦3Â÷¿¬¼ö±³À° : 2024-07-11 0 41 2024-05-28
20911 ¼­¿ï (¿Â¶óÀÎ) 2024³â ¼Ò¾Æ½ÅÀå Post-graduate education course : 2024-07-08 0 45 2024-05-28
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷